

10/26/01
JCS82 U.S. PTOPlease type a plus sign (+) inside this box

12-10-01

A/B/Box seq

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032
U S Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53 (b))

Attorney Docket No. LEX-0264-USA

First Inventor Walk and Scoville

Title Novel Human 7TM Proteins and Polynucleotides Encoding the Same

Express Mail Label No. EL864125623 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application

1. Fee Transmittal Form (e.g., PTO/SB/17)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 67]

 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the invention
 - Brief Summary of the Invention
 - Detailed Description
 - Claim(s)
 - Abstract of the disclosure
4. Drawing(s)(35 U.S.C.113) [Total Sheets]
5. Oath or Declaration [Total Pages 2]

 - a. Unexecuted
 - b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)
 - i. DELETION OF INVENTOR(S)
signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. diskette
 - ii. paper 5 pages
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney
11. English Translation Document (if applicable)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent
17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Prior application information:

Examiner _____

Group Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	 (Insert Customer No. or attach bar code label here)			<input type="checkbox"/> Correspondence address below
Name	PATENT TRADEMARK OFFICE			
Address				
City	State		Zip	
Country	Telephone		Fax	
Name (Print/Type)	Lance K. Ishimoto		Registration No. (Attorney/Agent)	41,866
Signature			Date	October 26, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)

Complete if Known

Application Number	To be assigned
Filing Date	10/26/01
First Named Inventor	Walke and Scoville
Examiner Name	To be assigned
Group Art Unit	To be assigned
Attorney Docket No.	LEX-0264-USA

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account Number	50-0892
Deposit Account Name	Lexicon Genetics Incorporated
<input type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	

2. **Payment Enclosed:**

Check Credit card Money Order Other

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
101	740	201	370 Utility filing fee
106	330	206	165 Design filing fee
107	510	207	255 Plant filing fee
108	740	208	370 Reissue filing fee
114	160	214	80 Provisional filing fee
SUBTOTAL (1)		(\$370.00)	

2. EXTRA CLAIM FEES

Paid	Extra Claims	Fee from below	Fee
Total Claims	5	-20** = 0	X = <input type="text"/>
Independent Claims	5	-3** = 2	X = <input type="text"/> 42 = <input type="text"/> 84.00
Multiple Dependent			= <input type="text"/>

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Description
103	18	203 9 Claims in excess of 20
102	84	202 42 Independent claims in excess of 3
104	280	204 140 Multiple dependent claim, if not paid
109	84	209 42 **Reissue independent claims over original patent
110	18	210 9 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 84.00)

**or number previously paid, if greater; For Reissues, see above


FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
105	130	205 65 Surcharge - late filing fee or oath	<input type="text"/>
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	<input type="text"/>
139	130	139 130 Non-English specification	<input type="text"/>
147	2,520	147 2,520 For filing a request for <i>ex parte</i> reexamination	<input type="text"/>
112	920*	112 920 Requesting publication of SIR prior to Examiner action	<input type="text"/>
113	1,840*	113 1,840* Requesting publication of SIR after	<input type="text"/>
115	110	215 55 Extension for reply within first month	<input type="text"/>
116	400	216 200 Extension for reply within second month	<input type="text"/>
117	920	217 460 Extension for reply within third month	<input type="text"/>
118	1,440	218 720 Extension for reply within fourth month	<input type="text"/>
128	1,960	228 980 Extension for reply within fifth month	<input type="text"/>
119	320	219 160 Notice of Appeal	<input type="text"/>
120	320	220 160 Filing a brief in support of an appeal	<input type="text"/>
121	280	221 140 Request for oral hearing	<input type="text"/>
138	1,510	138 1,510 Petition to institute a public use proceeding	<input type="text"/>
140	110	240 55 Petition to revive - unavoidable	<input type="text"/>
141	1,280	241 640 Petition to revive - unintentional	<input type="text"/>
142	1,280	242 640 Utility issue fee (or reissue)	<input type="text"/>
143	460	243 230 Design issue fee	<input type="text"/>
144	620	244 310 Plant issue fee	<input type="text"/>
122	130	122 130 Petitions to the Commissioner	<input type="text"/>
123	50	123 50 Processing fee under 37 CFR 1.17(q)	<input type="text"/>
126	180	126 180 Submission of Information Disclosure Stmt	<input type="text"/>
581	40	581 40 Recording each patent assignment per property (times number of properties)	<input type="text"/>
146	740	246 370 Filing a submission after final rejection (37 CFR § 1.129(a))	<input type="text"/>
149	740	249 370 For each additional invention to be examined (37 CFR § 1.129(b))	<input type="text"/>
179	740	279 370 Request for Continued Examination (RCE)	<input type="text"/>
169	900	169 900 Request for expedited examination of a design application	<input type="text"/>

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**SUBMITTED BY***Complete if applicable*

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866	Telephone	281-863-3333
Signature				Date	10/26/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Walke and Scoville

U.S. Ser. No.: To be assigned Attorney Docket No.: LEX-0264-USA

Filing Date: October 26, 2001

For: Novel Human 7TM and
Polynucleotides Encoding the Same

VERIFIED STATEMENT

Box Patent Application
Commission for Patents
Washington, D.C. 20231

Sir:

I, DRENDA D. THOMAS, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.

2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,



Drenda D. Thomas

October 26, 2001
Date